Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide

By Arndt C.A.S.   Nascimento A.G.   Schroeder G.   Schomberg P.J.   Neglia J.P.   Sencer S.F.   Silberman T.L.   Moertel C.L.   Tillisch J.K.   Miser J.S.  

European Journal of Cancer, Vol. 34, Iss. 8, 1998-07 ,pp. : 1224-1229

Elsevier

Access to resources Recommend Favorite

The Feasibility of Using Glycosylated Recombinant Human Granulocyte Colony-stimulating Factor (G-CSF) to Increase the Planned Dose Intensity of Doxorubicin, Cyclophosphamide and Etoposide (ACE) in the Treatment of Small Cell Lung Cancer

By Thatcher N.   Anderson H.   Bleehen N.M.   Girling D.J.   Lallemand G.   Machin D.   Stephens R.J.  

European Journal of Cancer, Vol. 31, Iss. 2, 1995-01 ,pp. : 152-156

Elsevier

Access to resources Recommend Favorite

Phase II Study of Celecoxib with Cisplatin Plus Etoposide in Extensive-Stage Small Cell Lung Cancer

By Araujo Antonio   Mendez Jose   Coelho Ana   Sousa Berta   Barata Fernando   Figueiredo Ana   Amaro Teresina   Azevedo Isabel   Soares Marta  

Cancer Investigation, Vol. 27, Iss. 4, 2009-05 ,pp. : 391-396

Informa Healthcare

Access to resources Recommend Favorite

A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study

By Foss Francine M.  

Leukemia and Lymphoma, Vol. 54, Iss. 7, 2013-07 ,pp. : 1373-1379

Informa Healthcare

Access to resources Recommend Favorite

A limited role for VEEP (vincristine, etoposide, epirubicin, prednisolone) chemotherapy in childhood Hodgkin's disease

By Shankar A.G.   Ashley S.   Atra A.   Kingston J.E.   Mott M.   Pinkerton C.R.  

European Journal of Cancer, Vol. 34, Iss. 13, 1998-12 ,pp. : 2058-2063

Elsevier

Access to resources Recommend Favorite